Press Release March 19, 2022U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma 0 0 Share
Company Ticker News March 17, 2022Bristol Myers Squibb: Consistently Hitting Targets, New Drug Launches Drive Share Price 0 0 Share
Company Ticker News March 17, 2022Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript) 0 0 Share
Press Release March 14, 2022Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma 0 0 Share
Company Ticker News March 14, 2022Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit 0 0 Share
Company Ticker News March 11, 2022Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022 0 0 Share
Company Ticker News March 9, 2022Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16 0 0 Share
Company Ticker News March 8, 2022FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication 0 0 Share
